Global Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market to Reach $54 Billion by 2030
The global market for Non-Small Cell Lung Cancer (NSCLC) Therapeutics estimated at US$24.6 Billion in the year 2022, is projected to reach a revised size of US$54 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2022-2030. Targeted Therapy, one of the segments analyzed in the report, is projected to record 11.7% CAGR and reach US$31.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Immunotherapy segment is readjusted to a revised 8.9% CAGR for the next 8-year period.The U.S. Market is Estimated at $6.7 Billion, While China is Forecast to Grow at 16.5% CAGR
The Non-Small Cell Lung Cancer (NSCLC) Therapeutics market in the U.S. is estimated at US$6.7 Billion in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$14.1 Billion by the year 2030 trailing a CAGR of 16.5% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.7% and 8.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 6.1% CAGR.Select Competitors (Total 34 Featured) -
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene Corp.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- GlaxoSmithKline plc
- Novartis
- Pfizer Inc.
- Roche Holding AG
- Sun Pharmaceutical Industries Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Impact of Covid-19 and a Looming Global Recession
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
- Table 2: World Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 3: World Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 4: World 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
- Table 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 8: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 9: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 10: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 13: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 14: World Recent Past, Current & Future Analysis for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 15: World Historic Review for Adenocarcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 16: World 16-Year Perspective for Adenocarcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 17: World Recent Past, Current & Future Analysis for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 18: World Historic Review for Squamous Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 19: World 16-Year Perspective for Squamous Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
- Table 20: World Recent Past, Current & Future Analysis for Large Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 21: World Historic Review for Large Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 22: World 16-Year Perspective for Large Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
UNITED STATES
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 23: USA Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 24: USA Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 25: USA 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 26: USA Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 27: USA Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 28: USA 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
CANADA
- Table 29: Canada Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: Canada Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 31: Canada 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 32: Canada Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: Canada Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 34: Canada 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
JAPAN
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 35: Japan Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Japan Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 37: Japan 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 38: Japan Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Japan Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 40: Japan 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
CHINA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 41: China Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: China Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 43: China 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 44: China Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: China Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 46: China 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
EUROPE
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 47: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 48: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 49: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
- Table 50: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 52: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 53: Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 55: Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
FRANCE
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 56: France Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: France Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 58: France 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 59: France Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: France Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 61: France 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
GERMANY
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 62: Germany Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: Germany Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 64: Germany 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 65: Germany Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: Germany Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 67: Germany 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
ITALY
- Table 68: Italy Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Italy Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 70: Italy 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 71: Italy Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Italy Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 73: Italy 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
UNITED KINGDOM
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 74: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: UK Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 76: UK 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 77: UK Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: UK Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 79: UK 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
SPAIN
- Table 80: Spain Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: Spain Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 82: Spain 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 83: Spain Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: Spain Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 85: Spain 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
RUSSIA
- Table 86: Russia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Russia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 88: Russia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 89: Russia Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Russia Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 91: Russia 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
REST OF EUROPE
- Table 92: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Rest of Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 94: Rest of Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 95: Rest of Europe Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Rest of Europe Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 97: Rest of Europe 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
ASIA-PACIFIC
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 99: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 100: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
- Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Targeted Therapy, Immunotherapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 103: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Immunotherapy and Chemotherapy for the Years 2014, 2023 & 2030
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2021 and % CAGR
- Table 106: Asia-Pacific 16-Year Perspective for Non-Small Cell Lung Cancer (NSCLC) Therapeutics by Histology - Percentage Breakdown of Value Sales for Adenocarcinoma, Squamous Cell Carcinoma and Large Cell Carcinoma for the Years 2014, 2023 & 2030
AUSTRALIA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene Corp.
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Genentech Inc.
- GlaxoSmithKline plc
- Novartis
- Pfizer Inc.
- Roche Holding AG
- Sun Pharmaceutical Industries Ltd.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 89 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 24.6 Billion |
Forecasted Market Value ( USD | $ 54 Billion |
Compound Annual Growth Rate | 10.3% |
Regions Covered | Global |